Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel, precision medicines for patients suffering from serious muscle disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company's mission is to change the lives of patients and families affected by these debilitating diseases by protecting muscle function and improving overall quality of life.

Edgewise Therapeutics leverages its expertise in muscle biology and small molecule drug discovery to build a proprietary, muscle-focused platform. Its lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor currently in late-stage clinical trials for Becker and Duchenne muscular dystrophies. The company's pipeline also includes EDG-7500, a novel cardiac sarcomere modulator in Phase 2 clinical development for hypertrophic cardiomyopathy (HCM) and other diastolic dysfunction diseases, and EDG-15400, a Phase 1 candidate for heart failure with preserved ejection fraction (HFpEF).

Recent notable developments include positive long-term data for sevasemten in Becker Muscular Dystrophy, demonstrating sustained functional stabilization through 3.5 years of follow-up, reported in March 2026. The company is led by President and CEO Kevin Koch and Co-Founder and Chief Scientific Officer Alan Russell. Edgewise Therapeutics positions itself as a leader in the muscle disease biopharmaceutical space, focusing on orally delivered small molecules that aim to reduce muscle damage and preserve function, offering a distinct approach in the treatment landscape for rare inherited muscle diseases.